AstraZeneca Unburdens Itself Of Brodalumab

AstraZeneca plc has managed to offload the dermatology candidate brodalumab to Valeant Pharmaceuticals International Inc following Amgen's decision to pull out of a co-development deal earlier this year. Amgen made the move owing to potential side effect issues, with suicidal thoughts being linked to brodalumab administration during clinical development, despite evidence of efficacy.

AstraZeneca plc has managed to offload the dermatology candidate brodalumab to Valeant Pharmaceuticals International Inc following Amgen's decision to pull out of a co-development deal earlier this year. Amgen made the move owing to potential side effect issues, with suicidal thoughts being linked to brodalumab administration during clinical development, despite evidence of efficacy.

AstraZeneca has now granted Valeant an exclusive license to develop and commercialize brodalumab, an IL-17 receptor monoclonal antibody in development...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Dermatological

More from Therapeutic Category